Developing the next generation of oncolytic immunotherapy.
Replimune’s powerful Immulytic™ platform combines multiple mechanisms to deliver medicines with the ability to not only directly kill cancer cells and generate systemic anti-cancer immune responses, but also create a practical approach to achieving personalized systemic neoantigen vaccination directly in the patient.
Our Immulytic™ platform consists of:
1) A potent proprietary viral strain: We selected herpes simplex virus (HSV) as the most potent viral species with the greatest potential to directly kill cancer cells and deliver additional therapeutic proteins into tumors. We then screened a large number of clinical isolates of HSV to pan the natural diversity of HSV and engineered the most effective strain which has become the proprietary backbone of our therapeutics.
2) Enhanced tumor killing and spread: We have armed our virus platform with a fusogenic protein that enhances the ability of HSV to kill cancer cells 10-100x by providing a large bystander effect. Cell to cell fusion causes immunogenic cell death, activating the adaptive and innate immune systems to provide systemic vaccination against the patient’s specific cancer directly in the patient.
3) Delivery of potent immune stimulating proteins: This platform is then used to deliver potent immune stimulating proteins directly to tumors and draining lymph nodes to augment and potentiate the anti-tumor immune response which is generated.
Our Immulytic™ platform is intended to achieve the holy grail of personalized anti-cancer vaccines – developing therapeutics tailored to all of a patient’s tumor antigens, including neoantigens – but in a much more practical way, directly in situ in the body. Our therapeutics are injected directly into the tumor to induce the most potent anti-tumor response. Intratumoral administration overcomes the problem of virus dilution and neutralization in the blood which occurs following IV administration of virus-based products.
Importantly, our approach is highly synergistic with immune checkpoint blockade and other immune-modulatory approaches, providing the potential to treat a broader range of patients and cancer types with immunotherapy.